Thema: News: Novel use of Gliadel for gliomas
News: Novel use of Gliadel for gliomas
Toni[a]
25.05.2002 21:47:12
Novel use of Gliadel for gliomas
Allan H Friedman, Sunil Agarwal, Brandon Evans, Amy Walker, Sandra Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney Beason, Sridharan Gururangan, Susanne Jackson, Roger McLendon, Jennifer Quinn, Jeremy Rich, John Sampson, Valerie Stafford-Fox, Karen Ziegler, Darell D Bigner, Henry Friedman, Duke University Medical Center, Durham, NC; Guilford Pharmaceuticals, Baltimore, MD; Pharmacia & Upjohn, Kalamazoo, MI; Schering-Plough, Kenilworth, NJ.
The Brain Tumor Center at Duke is conducting three trials utilizing Gliadel for the treatment of high-grade and low-grade gliomas. Two trials are currently being used for malignant glioma. A phase II trial of Gliadel plus temozolomide is being evaluated in patients with recurrent malignant glioma. Patients undergo surgical resection and placement of Gliadel wafers followed by temozolomide at a dose of 200 mg/m2/day for 5 days with cycles repeated every 4 weeks. Eight patients have been accrued to date with the following progression free survival: 48+, 36+, 24, 20+, 16, and 16 weeks, respectively. One patient refused therapy after 2 cycles. One patient was removed from study due to home physician advice. The second protocol, for patients with recurrent malignant glioma, is a phase I trial of Gliadel plus CPT-11. Patients undergo surgical resection with placement of Gliadel wafers followed by CPT-11 administered weekly x 4 with a 2 week rest. Thirteen patients have been accrued to date with the highest CPT-11 dose to date 100 mg/m2. The third protocol is a phase II trial of Gliadel for patients with recurrent low-grade glioma. Seven patients have been treated to date with the following progression free survivals: 40+, 36+, 26+, 27, 15, 7, and 4 months, respectively. In summary, this trial is building on the known anti-glioma activity of Gliadel with new multi-modality treatment strategies.
Source: ASCO 2002
Allan H Friedman, Sunil Agarwal, Brandon Evans, Amy Walker, Sandra Tourt-Uhlig, David Reardon, Mary L Affronti, Deborah Allen, Rodney Beason, Sridharan Gururangan, Susanne Jackson, Roger McLendon, Jennifer Quinn, Jeremy Rich, John Sampson, Valerie Stafford-Fox, Karen Ziegler, Darell D Bigner, Henry Friedman, Duke University Medical Center, Durham, NC; Guilford Pharmaceuticals, Baltimore, MD; Pharmacia & Upjohn, Kalamazoo, MI; Schering-Plough, Kenilworth, NJ.
The Brain Tumor Center at Duke is conducting three trials utilizing Gliadel for the treatment of high-grade and low-grade gliomas. Two trials are currently being used for malignant glioma. A phase II trial of Gliadel plus temozolomide is being evaluated in patients with recurrent malignant glioma. Patients undergo surgical resection and placement of Gliadel wafers followed by temozolomide at a dose of 200 mg/m2/day for 5 days with cycles repeated every 4 weeks. Eight patients have been accrued to date with the following progression free survival: 48+, 36+, 24, 20+, 16, and 16 weeks, respectively. One patient refused therapy after 2 cycles. One patient was removed from study due to home physician advice. The second protocol, for patients with recurrent malignant glioma, is a phase I trial of Gliadel plus CPT-11. Patients undergo surgical resection with placement of Gliadel wafers followed by CPT-11 administered weekly x 4 with a 2 week rest. Thirteen patients have been accrued to date with the highest CPT-11 dose to date 100 mg/m2. The third protocol is a phase II trial of Gliadel for patients with recurrent low-grade glioma. Seven patients have been treated to date with the following progression free survivals: 40+, 36+, 26+, 27, 15, 7, and 4 months, respectively. In summary, this trial is building on the known anti-glioma activity of Gliadel with new multi-modality treatment strategies.
Source: ASCO 2002
Toni[a]
